LENSAR (NASDAQ:LNSR) Issues Quarterly Earnings Results

LENSAR (NASDAQ:LNSR) released its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), FiscalAI reports. The business had revenue of $16.03 million for the quarter, compared to analysts’ expectations of $20.30 million.

Here are the key takeaways from LENSAR’s conference call:

• The planned acquisition by Alcon was mutually terminated after FTC opposition; LENSAR regained the $10 million escrow deposit and will continue as an independent company.
• Management says the ALLY Robotic Cataract Laser was validated by the acquisition interest and achieved ~200 installed systems (up ~48% year-over-year) and U.S. market share growth to 23.4%, supporting competitive strength.
• Recurring procedure revenue strengthened—2025 recurring revenue rose ~15% to $46.3 million (Q4 annualized >$50M) and comprised ~79% of Q4 revenue, providing higher-margin, predictable cash flow.
• International distributor uncertainty tied to the acquisition caused a meaningful slowdown in outside‑U.S. system sales (only one OUS sale in Q4), and management expects several quarters to rebuild OUS momentum.
• Despite ~$17.1M of merger-related charges and Q4 revenue of $16 million (down 4% YoY), LENSAR reported positive adjusted EBITDA for 2025, forecasts 46–49% gross margin in 2026, and expects ≤10% growth in cash-based operating expenses as it reactivates commercial efforts.

LENSAR Stock Up 0.1%

NASDAQ LNSR opened at $5.88 on Tuesday. The company has a market cap of $70.15 million, a PE ratio of -1.34 and a beta of 0.66. The firm’s 50-day simple moving average is $10.82 and its two-hundred day simple moving average is $11.31. LENSAR has a 52 week low of $5.35 and a 52 week high of $14.31.

Institutional Trading of LENSAR

A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new stake in LENSAR during the first quarter valued at approximately $546,000. Acadian Asset Management LLC purchased a new position in LENSAR in the 1st quarter worth approximately $257,000. Geode Capital Management LLC raised its holdings in LENSAR by 103.9% during the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock valued at $2,890,000 after buying an additional 111,802 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of LENSAR by 584.3% during the second quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock worth $62,000 after purchasing an additional 3,991 shares during the period. Finally, New York State Common Retirement Fund bought a new stake in shares of LENSAR in the 2nd quarter worth approximately $105,000. Hedge funds and other institutional investors own 40.15% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on LNSR. BTIG Research upgraded shares of LENSAR from a “neutral” rating to a “buy” rating in a report on Tuesday, March 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENSAR in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.